Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

See, E.J.; Jayasinghe, K.; Glassford, N.; Bailey, M.; Johnson, D.W.; Polkinghorne, K.R.; Toussaint, N.D.; Bellomo, R. Long-term

risk of adverse outcomes after acute kidney injury: A systematic review and meta-analysis of cohort studies using consensus

definitions of exposure. Kidney Int. 2019, 95, 160–172. [CrossRef]

Schmitt, R.; Coca, S.; Kanbay, M.; Tinetti, M.E.; Cantley, L.G.; Parikh, C.R. Recovery of kidney function after acute kidney injury

in the elderly: A systematic review and meta-analysis. Am. J. Kidney Dis. 2008, 52, 262–271. [CrossRef] [PubMed]

Ishani, A.; Xue, J.L.; Himmelfarb, J.; Eggers, P.W.; Kimmel, P.L.; Molitoris, B.A.; Collins, A.J. Acute kidney injury increases risk of

ESRD among elderly. J. Am. Soc. Nephrol. 2009, 20, 223–228. [CrossRef] [PubMed]

Thakar, C.V.; Christianson, A.; Himmelfarb, J.; Leonard, A.C. Acute kidney injury episodes and chronic kidney disease risk in

diabetes mellitus. Clin J. Am. Soc. Nephrol. 2011, 6, 2567–2572. [CrossRef]

Palomba, H.; Castro, I.; Yu, L.; Burdmann, E.A. The duration of acute kidney injury after cardiac surgery increases the risk of

long-term chronic kidney disease. J. Nephrol. 2017, 30, 567–572. [CrossRef]

Petrenko, Y.; Syková, E.; Kubinová, Š. The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell

spheroids. Stem Cell Res. Ther. 2017, 8, 94. [CrossRef]

Chen, Y.T.; Sun, C.K.; Lin, Y.C.; Chang, L.T.; Chen, Y.L.; Tsai, T.H.; Chung, S.Y.; Chua, S.; Kao, Y.H.; Yen, C.H.; et al. Adiposederived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and

inflammatory reaction. J. Transl. Med. 2011, 9, 51. [CrossRef] [PubMed]

Ashour, R.H.; Saad, M.A.; Sobh, M.A.; Al-Husseiny, F.; Abouelkheir, M.; Awad, A.; Elghannam, D.; Abdel-Ghaffar, H.; Sobh, M.

Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in SpragueDawley rats. Stem Cell Res. Ther. 2016, 7, 126. [CrossRef]

Duffield, J.S.; Park, K.M.; Hsiao, L.L.; Kelley, V.R.; Scadden, D.T.; Ichimura, T.; Bonventre, J.V. Restoration of tubular epithelial

cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J. Clin. Investig. 2005,

115, 1743–1755. [CrossRef] [PubMed]

Lange, C.; Tögel, F.; Ittrich, H.; Clayton, F.; Nolte-Ernsting, C.; Zander, A.R.; Westenfelder, C. Administered mesenchymal stem

cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 2005, 68, 1613–1617. [CrossRef]

Cai, J.; Yu, X.; Xu, R.; Fang, Y.; Qian, X.; Liu, S.; Teng, J.; Ding, X. Maximum efficacy of mesenchymal stem cells in rat model of

renal ischemia-reperfusion injury: Renal artery administration with optimal numbers. PLoS ONE 2014, 9, e92347. [CrossRef]

Int. J. Mol. Sci. 2021, 22, 4178

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

11 of 11

Luo, C.J.; Zhang, F.J.; Zhang, L.; Geng, Y.Q.; Li, Q.G.; Hong, Q.; Fu, B.; Zhu, F.; Cui, S.Y.; Feng, Z.; et al. Mesenchymal stem cells

ameliorate sepsis-associated acute kidney injury in mice. Shock 2014, 41, 123–129. [CrossRef]

Asanuma, H.; Vanderbrink, B.A.; Campbell, M.T.; Hile, K.L.; Zhang, H.; Meldrum, D.R.; Meldrum, K.K. Arterially delivered

mesenchymal stem cells prevent obstruction-induced renal fibrosis. J. Surg. Res. 2011, 168, e51–e59. [CrossRef]

Ishiuchi, N.; Nakashima, A.; Doi, S.; Yoshida, K.; Maeda, S.; Kanai, R.; Yamada, Y.; Ike, T.; Doi, T.; Kato, Y.; et al. Hypoxiapreconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats. Stem Cell Res. Ther.

2020, 11, 130. [CrossRef]

Thadhani, R.; Pascual, M.; Bonventre, J.V. Acute renal failure. N. Engl. J. Med. 1996, 334, 1448–1460. [CrossRef] [PubMed]

Kraitchman, D.L.; Tatsumi, M.; Gilson, W.D.; Ishimori, T.; Kedziorek, D.; Walczak, P.; Segars, W.P.; Chen, H.H.; Fritzges, D.;

Izbudak, I.; et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005,

112, 145–161. [CrossRef] [PubMed]

Walczak, P.; Zhang, J.; Gilad, A.A.; Kedziorek, D.A.; Ruiz-Cabello, J.; Young, R.G.; Pittenger, M.F.; van Zijl, P.C.; Huang, J.; Bulte,

J.W. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008,

39, 1569–1574. [CrossRef]

Bonventre, J.V. Mechanisms of ischemic acute renal failure. Kidney Int. 1993, 43, 1160–1178. [CrossRef] [PubMed]

Toma, C.; Pittenger, M.F.; Cahill, K.S.; Byrne, B.J.; Kessler, P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte

phenotype in the adult murine heart. Circulation 2002, 105, 93–98. [CrossRef]

Sasaki, M.; Abe, R.; Fujita, Y.; Ando, S.; Inokuma, D.; Shimizu, H. Mesenchymal stem cells are recruited into wounded skin and

contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 2008, 180, 2581–2587. [CrossRef]

Liu, P.; Feng, Y.; Dong, C.; Yang, D.; Li, B.; Chen, X.; Zhang, Z.; Wang, Y.; Zhou, Y.; Zhao, L. Administration of BMSCs with

muscone in rats with gentamicin-induced AKI improves their therapeutic efficacy. PLoS ONE 2014, 9, e97123. [CrossRef]

[PubMed]

McIntyre, L.A.; Stewart, D.J.; Mei, S.H.J.; Courtman, D.; Watpool, I.; Granton, J.; Marshall, J.; Santos, C.D.; Walley, K.R.; Winston,

B.W.; et al. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. Am. J. Respir. Crit. Care Med. 2018, 197, 337–347.

[CrossRef]

Swaminathan, M.; Stafford-Smith, M.; Chertow, G.M.; Warnock, D.G.; Paragamian, V.; Brenner, R.M.; Lellouche, F.; Fox-Robichaud,

A.; Atta, M.G.; Melby, S.; et al. Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. J. Am. Soc.

Nephrol. 2018, 29, 260–267. [CrossRef] [PubMed]

Moll, G.; Ankrum, J.A.; Kamhieh-Milz, J.; Bieback, K.; Ringdén, O.; Volk, H.D.; Geissler, S.; Reinke, P. Intravascular Mesenchymal

Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol. Med. 2019, 25, 149–163.

[CrossRef]

Barbash, I.M.; Chouraqui, P.; Baron, J.; Feinberg, M.S.; Etzion, S.; Tessone, A.; Miller, L.; Guetta, E.; Zipori, D.; Kedes, L.H.; et al.

Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and

body distribution. Circulation 2003, 108, 863–868. [CrossRef]

Tatsumi, K.; Ohashi, K.; Matsubara, Y.; Kohori, A.; Ohno, T.; Kakidachi, H.; Horii, A.; Kanegae, K.; Utoh, R.; Iwata, T.; et al.

Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem. Biophys. Res.

Commun. 2013, 431, 203–209. [CrossRef]

George, M.J.; Prabhakara, K.; Toledano-Furman, N.E.; Wang, Y.W.; Gill, B.S.; Wade, C.E.; Olson, S.D.; Cox, C.S., Jr. Clinical

Cellular Therapeutics Accelerate Clot Formation. Stem Cells Transl. Med. 2018, 7, 731–739. [CrossRef]

Yoshida, K.; Nakashima, A.; Doi, S.; Ueno, T.; Okubo, T.; Kawano, K.I.; Kanawa, M.; Kato, Y.; Higashi, Y.; Masaki, T. Serum-Free

Medium Enhances the Immunosuppressive and Antifibrotic Abilities of Mesenchymal Stem Cells Utilized in Experimental Renal

Fibrosis. Stem Cells Transl. Med. 2018, 7, 893–905. [CrossRef]

Ueno, T.; Nakashima, A.; Doi, S.; Kawamoto, T.; Honda, K.; Yokoyama, Y.; Doi, T.; Higashi, Y.; Yorioka, N.; Kato, Y.; et al.

Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1

signaling. Kidney Int. 2013, 84, 297–307. [CrossRef]

Nakashima, A.; Kawamoto, T.; Honda, K.K.; Ueshima, T.; Noshiro, M.; Iwata, T.; Fujimoto, K.; Kubo, H.; Honma, S.; Yorioka, N.;

et al. DEC1 modulates the circadian phase of clock gene expression. Mol. Cell. Biol. 2008, 28, 4080–4092. [CrossRef] [PubMed]

...